サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1757484

治療薬の世界市場

Curative Therapeutics

出版日
ページ情報
英文 390 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.81円
治療薬の世界市場
出版日: 2025年06月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 390 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

治療薬の世界市場は2030年までに6億5,510万米ドルに達する見込み

2024年に4億7,400万米ドルと推定される治療薬の世界市場は、分析期間2024-2030年にCAGR 5.5%で成長し、2030年には6億5,510万米ドルに達すると予測されます。本レポートで分析したセグメントの1つである生物学的修飾薬は、CAGR 5.9%を記録し、分析期間終了時には4億3,660万米ドルに達すると予想されます。遺伝子治療薬セグメントの成長率は、分析期間中CAGR 4.4%と推定されます。

米国市場は1億2,910万米ドルと推定、中国はCAGR 8.8％で成長予測

米国の治療薬市場は、2024年に1億2,910万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを8.8%として、2030年までに1億3,220万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.7%と5.5%と予測されています。欧州では、ドイツがCAGR 3.6%で成長すると予測されています。

世界の治療薬市場- 主要動向と促進要因のまとめ

治療薬の定義と現代ヘルスケアを形成する理由とは？

治療薬とは、単に症状を管理したり進行を遅らせるのではなく、疾患の根本原因を取り除くことを目的とした治療や介入を指します。従来の慢性疾患管理アプローチとは異なり、根治療法は、外科的矯正、細胞や遺伝子の改変、病原体の根絶などを通じて、しばしば健康を完全に回復させる可能性を提供します。このような治療は、遺伝子疾患、腫瘍学、感染症、希少代謝疾患などの分野において、特に大きな変革をもたらしています。

分子医学、再生療法、高精度薬物標的療法における科学的飛躍的進歩に後押しされ、このような維持から治癒へのシフトは、世界のヘルスケアアジェンダの中で重要性を増しています。ゲノム編集、幹細胞生物学、免疫療法などの開発により、以前は治療不可能と考えられていた疾患に対する治療法の開発が可能になりました。ヘルスケアシステムが長期的なアウトカムと費用対効果をますます優先するようになる中、治療薬は生涯医療費を削減し、生活の質を向上させ、ある種の疾病負担を完全に根絶する可能性のある強力なツールとみなされています。

テクノロジー・プラットフォームとモダリティは、どのように治癒的治療法の台頭を後押ししているのか？

治療薬の進化は、生物製剤、遺伝子編集プラットフォーム、個別化医療における革新と密接に結びついています。最も顕著な開発のひとつは遺伝子治療で、CRISPR/Cas9やウイルスベクター送達システムのような技術により、病気の原因となる変異の永久的な修正が可能になっています。脊髄性筋萎縮症や遺伝性網膜疾患のような疾患に対して承認された遺伝子治療は、このアプローチを検証し、血友病、βサラセミア、免疫不全症など、より広範な分野への応用の舞台を整えました。

細胞ベースの治療法、特に自己幹細胞や同種幹細胞を用いた治療法は、血液悪性腫瘍、神経変性疾患、心臓修復などの再生医療への応用で人気を集めています。一方、CAR-T細胞治療などの免疫療法は、患者の免疫系を再プログラムしてがんを排除することにより、特定のリンパ腫や白血病において治癒の可能性を示しています。さらに、低分子抗ウイルス薬や抗菌薬の画期的な進歩により、C型肝炎のような慢性感染症に対する治療レジメンが提供されつつあり、治療期間が短縮され、奏効率も持続しています。

どのような治療領域と患者セグメントが採用を促進しているか？

治療薬が最も大きな影響を及ぼしているのは、希少疾患や遺伝性疾患です。遺伝性疾患を持つ小児患者は、早期介入によって疾患の経過を大きく変えることができるため、有力な候補となります。同様に、腫瘍学においても治癒を目的とした治療が行われるようになってきており、特定のがんに対しては、完全寛解や根絶を目指し、手術、免疫療法、分子標的薬などを組み合わせた多剤併用療法が行われています。

感染症管理も重要な領域であり、特に慢性ウイルス感染症では、世界の撲滅戦略において治癒を目的とした薬物療法が優先されています。これと並行して、糖尿病や心不全のような慢性疾患のカテゴリーでは、疾患逆転の可能性を秘めた再生療法や細胞ベースの治療法が初期段階で研究されています。従来の治療が奏功しなかった高リスクまたは難治性の患者は、治癒を目的とした治療法の臨床試験や承認のための早期採用基盤の大部分を占めています。

治療薬の世界市場成長を促進する要因は？

治療薬市場の成長は、科学的イノベーション、アンメット・メディカル・ニーズ、長期的ヘルスケア経済と結びついたいくつかの要因によって牽引されています。先進的な生物製剤、遺伝子編集プラットフォーム、細胞療法への投資の増加により、複数の疾患領域における治療薬候補のパイプラインが加速しています。慢性的で生涯続く疾患の臨床的・経済的負担が大きいことから、支払者や規制当局の間では、長期にわたる持続的な救済とコスト相殺を提供する治癒モデルを支援することが急務となっています。

画期的治療薬の迅速な承認、希少疾病用医薬品のステータス、優先審査など、規制当局の強力な推進力により、より迅速な承認が可能となり、治療領域における研究開発のインセンティブが高まっています。希少疾患や遺伝性疾患に対する世界の認識と支持の高まりは、臨床試験への登録と早期診断を増加させ、治療的介入をタイムリーに展開することを可能にしています。最後に、バイオマーカーとコンパニオン診断薬を活用した精密医療アプローチにより、これらの治療薬が効果的に標的を絞り込まれ、治療の成功率が最大化されています。これらの要因が相まって、治癒はもはや夢物語ではなく、ますます実現可能なものとなり、ヘルスケア提供における変革的なシフトに拍車がかかっています。

セグメント

タイプ（生物学的変化治療薬、遺伝子治療薬、細胞治療薬）、適応症（がん適応症、筋骨格系疾患適応症、神経変性疾患適応症、希少疾患適応症、C型肝炎適応症、その他適応症）、エンドユーザー（製薬企業エンドユーザー、学術・研究機関エンドユーザー、その他エンドユーザー）

調査対象企業の例（注目の合計48社）

  • Alnylam Pharmaceuticals
  • Beam Therapeutics
  • Bluebird bio
  • Cartesian Therapeutics
  • CRISPR Therapeutics
  • Curative Biotechnology
  • CureAge Therapeutics
  • Gilead Sciences
  • GlaxoSmithKline（GSK）
  • Intellia Therapeutics
  • Jnana Therapeutics
  • Kymera Therapeutics
  • MiNA Therapeutics
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sarepta Therapeutics
  • Seagen Inc.
  • Spark Therapeutics
  • Vertex Pharmaceuticals

AI統合

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革します。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP36644

Global Curative Therapeutics Market to Reach US$655.1 Million by 2030

The global market for Curative Therapeutics estimated at US$474.0 Million in the year 2024, is expected to reach US$655.1 Million by 2030, growing at a CAGR of 5.5% over the analysis period 2024-2030. Biology Modifying Drugs, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$436.6 Million by the end of the analysis period. Growth in the Gene Therapies segment is estimated at 4.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$129.1 Million While China is Forecast to Grow at 8.8% CAGR

The Curative Therapeutics market in the U.S. is estimated at US$129.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$132.2 Million by the year 2030 trailing a CAGR of 8.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Curative Therapeutics Market - Key Trends & Drivers Summarized

What Defines Curative Therapeutics and Why Are They Reshaping Modern Healthcare?

Curative therapeutics refer to treatments or interventions that aim to eliminate the root cause of a disease rather than merely managing symptoms or slowing progression. Unlike traditional chronic disease management approaches, curative therapies offer the potential for complete restoration of health-often through surgical correction, cell or gene modification, or pathogen eradication. These treatments are particularly transformative in areas such as genetic disorders, oncology, infectious diseases, and rare metabolic conditions.

This shift from maintenance to cure is gaining prominence in the global healthcare agenda, fueled by scientific breakthroughs in molecular medicine, regenerative therapies, and precision drug targeting. Advances in genomic editing, stem cell biology, and immunotherapy have enabled the development of curative options for diseases previously considered untreatable. As healthcare systems increasingly prioritize long-term outcomes and cost-effectiveness, curative therapeutics are seen as a powerful tool to reduce lifetime healthcare expenditures, improve quality of life, and potentially eradicate certain disease burdens altogether.

How Are Technology Platforms and Modalities Powering the Rise of Curative Therapies?

The evolution of curative therapeutics is closely tied to innovation in biologics, gene editing platforms, and personalized medicine. One of the most prominent developments has been in gene therapies, where techniques like CRISPR/Cas9 and viral vector delivery systems are enabling permanent correction of disease-causing mutations. Approved gene therapies for conditions like spinal muscular atrophy or inherited retinal diseases have validated this approach and set the stage for broader application in hemophilia, beta-thalassemia, and immune deficiencies.

Cell-based therapies, particularly those involving autologous or allogeneic stem cells, are gaining traction for regenerative applications in hematologic malignancies, neurodegenerative diseases, and cardiac repair. Meanwhile, immunotherapies such as CAR-T cell treatments have demonstrated curative potential in certain lymphomas and leukemias by reprogramming the patient’s immune system to eliminate cancer. Additionally, breakthroughs in small-molecule antivirals and antimicrobial agents are offering curative regimens for chronic infectious diseases like hepatitis C, with shorter treatment durations and durable response rates.

Which Therapeutic Areas and Patient Segments Are Driving Adoption?

The most significant impact of curative therapeutics is being observed in rare diseases and genetic disorders, where a one-time intervention can replace a lifetime of symptomatic management. Pediatric patients with inherited conditions are prime candidates, as early intervention can significantly alter disease trajectory. Similarly, curative intent is increasingly targeted in oncology, where certain cancers are being approached with multimodal strategies combining surgery, immunotherapy, and targeted agents aimed at complete remission or eradication.

Infectious disease management is another key domain, especially for chronic viral infections where curative drug regimens are being prioritized in global elimination strategies. In parallel, chronic disease categories such as diabetes or heart failure are witnessing early-stage investigations into regenerative and cell-based therapies with the potential for disease reversal. Patients in high-risk or refractory categories, where conventional treatments have failed, represent a major portion of the early adoption base for curative therapeutic trials and approvals.

What Factors Are Driving Market Growth for Curative Therapeutics Globally?

The growth in the curative therapeutics market is driven by several factors tied to scientific innovation, unmet medical needs, and long-term healthcare economics. Increasing investment in advanced biologics, gene editing platforms, and cellular therapies is accelerating the pipeline of curative candidates across multiple disease areas. The high clinical and economic burden of chronic, lifelong diseases is creating urgency among payers and regulators to support curative models that offer durable relief and cost offset over time.

Strong regulatory momentum-including expedited pathways for breakthrough therapies, orphan drug status, and priority reviews-is enabling faster approvals and incentivizing R&D in curative domains. Rising global awareness and advocacy around rare and genetic diseases are increasing trial enrollment and early diagnosis, allowing timely deployment of curative interventions. Lastly, precision medicine approaches powered by biomarkers and companion diagnostics are ensuring that these therapies are effectively targeted, maximizing therapeutic success. Collectively, these drivers are fueling a transformative shift in healthcare delivery, where curative outcomes are no longer aspirational but increasingly achievable.

SCOPE OF STUDY:

The report analyzes the Curative Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Biology Modifying Drugs, Gene Therapies, Cell Therapies); Indication (Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication, Other Indications); End-Use (Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • Alnylam Pharmaceuticals
  • Beam Therapeutics
  • Bluebird bio
  • Cartesian Therapeutics
  • CRISPR Therapeutics
  • Curative Biotechnology
  • CureAge Therapeutics
  • Gilead Sciences
  • GlaxoSmithKline (GSK)
  • Intellia Therapeutics
  • Jnana Therapeutics
  • Kymera Therapeutics
  • MiNA Therapeutics
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sarepta Therapeutics
  • Seagen Inc.
  • Spark Therapeutics
  • Vertex Pharmaceuticals

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Curative Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Chronic and Rare Diseases Propels Growth in Curative Therapeutics R&D
    • Breakthroughs in Cell and Gene Therapy Strengthen Business Case for One-Time, Curative Treatments
    • Regulatory Acceleration for Orphan Drug Approvals Throws the Spotlight on Fast-Tracked Therapies
    • Shift from Maintenance Drugs to Functional Cures Drives Strategic Investment in Biotech Pipelines
    • Precision Medicine Advancements Fuel Personalized Curative Treatment Modalities
    • Growing Payer Willingness to Support High-Value, Long-Term Cure Models Sustains Market Adoption
    • Expansion of Clinical Trials in Genetic Disorders Accelerates Curative Therapy Commercialization
    • Emergence of Regenerative Therapies in Musculoskeletal and Neurological Diseases Drives Pipeline Diversification
    • Focus on Rare Pediatric Diseases Strengthens Public-Private Research Collaborations
    • Investment Surge in mRNA and CRISPR-Based Curative Platforms Opens New Market Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Curative Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Curative Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Curative Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Curative Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Biology Modifying Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Biology Modifying Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Biology Modifying Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Gene Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Gene Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Gene Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Cell Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Cell Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Cell Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Pharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Academic & Research Institutions End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Academic & Research Institutions End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Academic & Research Institutions End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Cancer Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Musculoskeletal Disorders Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Musculoskeletal Disorders Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Musculoskeletal Disorders Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Neurodegenerative Diseases Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Neurodegenerative Diseases Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Neurodegenerative Diseases Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Rare Diseases Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Rare Diseases Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Rare Diseases Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Hepatitis C Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Hepatitis C Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Hepatitis C Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Curative Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Canada 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • JAPAN
    • Curative Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Japan 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • CHINA
    • Curative Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: China 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: China 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: China 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • EUROPE
    • Curative Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Curative Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Curative Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Curative Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Europe 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • FRANCE
    • Curative Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 89: France Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: France 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: France 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: France 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • GERMANY
    • Curative Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Germany 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: Italy 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Curative Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 116: UK Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: UK 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Spain 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Russia 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Curative Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Curative Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Curative Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Curative Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Curative Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Australia 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • INDIA
    • Curative Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 173: India Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: India 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: India 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: India 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: South Korea 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Curative Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Curative Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Curative Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Curative Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Latin America 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: Argentina 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: Brazil 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: Mexico 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Curative Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Curative Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Curative Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Curative Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Middle East 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Iran 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: Israel 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: UAE 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030
  • AFRICA
    • Curative Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Curative Therapeutics by Type - Biology Modifying Drugs, Gene Therapies and Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Curative Therapeutics by Type - Percentage Breakdown of Value Sales for Biology Modifying Drugs, Gene Therapies and Cell Therapies for the Years 2014, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Curative Therapeutics by End-Use - Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Curative Therapeutics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academic & Research Institutions End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Curative Therapeutics by Indication - Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 313: Africa 16-Year Perspective for Curative Therapeutics by Indication - Percentage Breakdown of Value Sales for Cancer Indication, Musculoskeletal Disorders Indication, Neurodegenerative Diseases Indication, Rare Diseases Indication, Hepatitis C Indication and Other Indications for the Years 2014, 2025 & 2030

IV. COMPETITION